The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > BUSINESS
BUSINESS
- Bayer Seeks New Indications for Antibiotic Ciproxan
November 4, 2014
- AnGes MG to Initiate Multinational PIII Study of Collategene in Europe
November 4, 2014
- Takeda Aims for Consecutive Sales Growth through FY2022
October 31, 2014
- Sumitomo Dainippon’s Sales Down 1.7% on Drug Price Cuts in Japan
October 31, 2014
- Eisai Flounders in Japan, US Markets, Half-Year Profits Dive 60%
October 31, 2014
- Takeda Reports 2.8% Rise in First-Half Sales
October 31, 2014
- MTPC Files Remicade for Behcet’s Disease with Special Lesions
October 31, 2014
- Smaller Crestor Royalties Send Shionogi’s April-Sept. Sales Lower
October 30, 2014
- MTPC’s Half-Year Sales Dip, but Operating Profit Jumps on Gilenya Royalties
October 30, 2014
- Chugai to Supply Tamiflu for 7 Million Persons This Flu Season
October 30, 2014
- GPCR Consortium, an International Partnership of Industry and Academia, Established: Ono
October 30, 2014
- Safety of Lorcaserin Confirmed in Concomitant Administration with Phentermine: Eisai
October 30, 2014
- Fujifilm to Buy US Vaccine CMO
October 29, 2014
- Mario Stein Named as New President of J&J Consumer Company
October 29, 2014
- Bristol’s Involvement in Sprycel Trial Could Contravene Ethics Code, but Not PAL: Probe
October 28, 2014
- US Judge Cuts Damages Takeda to Pay over Actos from US$6 Billion to US$27.65 Million
October 28, 2014
- GSK Files Lamictal Monotherapy for Typical Absence Seizures in Pediatric Patients
October 28, 2014
- NBI Files Spiriva-LABA Combination Drug for Approval
October 28, 2014
- 3 Major Wholesalers Acknowledge Illegal Diversion of Ethical Drugs to Wholesalers
October 28, 2014
- Xtandi Receives Positive CHMP Opinion for Treatment of Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer: Astellas
October 28, 2014
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…